Healthcare Professionals

At Zafgen, we’re working to advance safe, effective treatment options that have the potential to significantly improve the health and well-being of patients affected by a range of both rare and more prevalent metabolic disorders where MetAP2 plays a central role. We know that especially in the case of serious and rare metabolic disorders, physicians are waiting for options for their patients, and we are committed to working alongside the community to deliver on the potential of MetAP2 inhibition to positively impact patients’ lives.

Clinical Trials

Zafgen is developing a range of potential first-in-class therapies for type 2 diabetes and other complex metabolic conditions.

ZGN-1061 for the treatment of type 2 diabetes

ZGN-1061 is Zafgen’s second-generation, investigational MetAP2 inhibitor for the treatment of type 2 diabetes. We reported positive full 12-week results for our Phase 2 proof-of-concept trial and are advancing ZGN-1061 through additional ex-U.S. Phase 2 clinical development, including a 1.8 mg dose cohort of the trial which is fully enrolled and dosing has been completed.

The FDA has placed a clinical hold on the Investigational New Drug Application (IND) for the company’s first U.S. clinical trial of ZGN-1061.

ZGN-1258 for Prader-Willi syndrome

Zafgen is completing the investigational new drug application (IND) enabling studies necessary for submission of an IND to the U.S. Food and Drug Administration. The company plans to first initiate a Phase 1 clinical trial of ZGN-1258 in non-PWS participants, and then select a target dose range prior to initiating clinical trials for people with PWS.

As part of our commitment to the PWS community, Zafgen has also launched a natural history study, PATH for PWS, co-sponsored by the Foundation for Prader-Willi Research, to collect insights into the medical and clinical histories of people with PWS. Among other benefits to the community, this study will also help inform Zafgen’s ZGN-1258 development program. Enrollment in the PATH for PWS natural history study is underway, and more information is available at www.PATHforPWS.com

For more information or questions about trial participation, please contact us at info@zafgen.com.